Company Summary - Abcam PLC (LSE:ABC)
912.50p
7.50p
(-0.82%)
FTSE AIM UK 50 Pharmaceuticals & BiotechnologyMarket cap: £321.693m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development, marketing and selling of antibodies and related products
| Financials - Annual Report (30/06/2009) | ||
|---|---|---|
| Turnover | £m | 56.8 |
| Pre-tax Profit | £m | 16.3 |
| EPS | p | 38.16 |
| DPS | p | 7.27 |
| Dividend Yield | % | .797 |
| Director | Board Role |
|---|---|
| Michael Redmond | Chairman |
| Dr. Jonathan Milner | Chief Executive |
| Jeff Iliffe | Finance Director |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Abcam Inc; Abcam KK
Broker Sentiment (7 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Additional Listing | 16/11/2009 |
| Director/PDMR Shareholding | 09/11/2009 |
| Director/PDMR Shareholding | 09/11/2009 |